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Abstract: 
 Poorly-defined interactions between environmental and genetic risk factors underlie Parkinson's 
disease (PD) etiology. Here we tested the hypothesis that human stem cell derived forebrain 
neuroprogenitors from patients with known familial risk for early onset PD will exhibit enhanced 
sensitivity to PD environmental risk factors compared to healthy control subjects without a 
family history of PD. Two male siblings (SM and PM) with biallelic loss-of-function mutations 
in PARK2 were identified. Human induced pluripotent stem cells(hiPSCs) from SM, PM, and 
four control subjects with no known family histories of PD or related neurodegenerative diseases 
were utilized. We tested the hypothesis that hiPSC-derived neuroprogenitors from patients 
with PARK2 mutations would show heightened cell death, mitochondrial dysfunction, and 
reactive oxygen species generation compared to control cells as a result of exposure to heavy 
metals (PD environmental risk factors). We report that PARK2 mutant neuroprogenitors showed 
increased cytotoxicity with copper (Cu) and cadmium (Cd) exposure but not manganese (Mn) or 
methyl mercury (MeHg) relative to control neuroprogenitors. PARK2 mutant neuroprogenitors 
also showed a substantial increase in mitochondrial fragmentation, initial ROS generation, and 
loss of mitochondrial membrane potential following Cu exposure. Our data substantiate Cu 
exposure as an environmental risk factor for PD. Furthermore, we report a shift in the lowest 
observable effect level (LOEL) for greater sensitivity to Cu-dependent mitochondrial 
dysfunction in patients SM and PM relative to controls, correlating with their increased genetic 
risk for PD. 
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Introduction 
Parkinson's disease (PD) is characterized by progressive motor function decline due to loss of 
dopaminergic neurons in the substantia nigra (SN). A minority of PD patients (familial PD) have 
single gene mutations associated with disease etiology (~ 10% of cases). The remaining 
idiopathic PD cases are influenced by interactions of genetic and environmental risk factors, 
including exposure to heavy metals and pesticides (Betarbet et al., 2000, Gorell et al., 
1999, Gorell et al., 1998 and Jomova et al., 2010). The role of environmental factors is 
underscored by a high discordance between monozygotic twins (Tanner et al., 1999). 
Mutations of PARK2 are one of the most common causes of early onset PD (EOPD) ( Kitada et 
al., 1998). Despite this association, patients with biallelic loss-of-function PARK2 mutations can 
have incomplete penetrance with high intra-familial and inter-familial variability in ages of onset 
( Abbas et al., 1999, Deng et al., 2006 and Khan et al., 2003). For example, one study found a 
56-year old subject with compound heterozygous mutations in PARK2 exhibiting no evidence of 
PD despite having four siblings with the samePARK2 mutation that were diagnosed with EOPD 
at ages from 30 to 38 ( Deng et al., 2006). Therefore, we hypothesized that biallelic loss-of-
function PARK2 mutations would increase sensitivity to PD-associated environmental risk 
factors. 
Recently, differentiated neural lineages from hiPSCs of patients with PARK2 mutations have 
been reported to exhibit mitochondrial dysfunction and increased oxidative stress ( Imaizumi et 
al., 2012). Both these phenotypes have separately been associated with exposures to heavy 
metals ( Jomova et al., 2010). Here we performed a proof-of-principle assessment of PD-relevant 
toxicant vulnerability in two subjects (SM and PM) with compound heterozygous loss-of-
function mutations in PARK2 versus control subjects. We utilized hiPSCs that are differentiated 
into neuroprogenitors that retain the unique genetic information of each human subject. Toxicant 
sensitivities at this early neurodevelopmental time point are pertinent given the strong evidence 
for in utero and early life environmental insults contributing to subsequent risk for PD ( de la 
Fuente-Fernández and Calne, 2002 and Landrigan et al., 2005). 
Methods 
Human subjects, clinical findings, generation of hiPSC lines 
Primary dermal fibroblasts were obtained by skin biopsy from healthy adult subjects (CA, CE, 
CF) with no known family history or genetic risk factors for PD and two PD patients (PM and 
SM) after appropriate patient consent/assent under the guidelines of an approved IRB protocol 
(Vanderbilt #080369). The MRC-5 fibroblasts (obtained from Coriell Institute for Medical 
Research and designated CB) were originally derived from a 14-week fetus aborted for maternal 
psychiatric reasons from a 27 year-old physically healthy woman with no known family history 
or genetic risk factors for PD. The studied patient PM was diagnosed with EOPD in his 30s and 
had dystonia from age 12 and resting tremor at age 17. He began having gait difficulties at age 
23. Medical genetic analysis was performed, and biallelic mutations in the PARK2 locus were 
identified. The studied patient SM, brother of PM, was diagnosed at the Vanderbilt University 
Medical Center Movement Disorders Clinic with exercise-induced dystonia. Given his family 
history, SM also underwent genetic testing revealing the same compound heterozygous 
mutations in PARK2 as his brother PM. SM had a normal neurological exam by a movement 
disorders specialist at age 40 – the time of the skin biopsy – with no evidence of baseline 
dystonia or parkinsonism at that time. However, a clinical DaTScan via SPECTimaging later 
revealed bilateral dopaminergic denervation in the putamen with relative preservation of 
caudate and led to his current diagnosis of preclinical PD. Patients SM and PM reported no 
known exposures to heavy metals or other PD-relevant environmental risk factors such as 
pesticides. Furthermore, there was no evidence of any additional occupational-related exposures. 
Fibroblasts and hiPSCs were cultured as described previously ( Neely et al., 2012). hiPSC lines 
CA4, CA6, CB5, SM3, SM4, and SM5 were reprogrammed using viral vectors whereas hiPSC 
lines CA11, CE6, CF1, SM14, PM12 and PM17 were reprogrammed using an episomal-based 
method ( Okita et al., 2011 and Takahashi et al., 2007). Line nomenclature follows an 
alphanumeric sequence, wherein the first two letters designate the human subject they are 
derived from. The sequential numbers identify individual clones picked from the original 
reprogramming plate (e.g. SM14 comes from the 14th iPSC colony isolated from this subject). 
The two-letter subject code does not contain patient identifying characteristics. Validation of 
most hiPSC lines used in this study has been previously published ( Neely et al., 
2012 and Srinivasakumar et al., 2013). Additional lines underwent and passed the same 
validation. For example, see the Supplemental materials (Figure S1). Like our previously 
published lines, new hiPSC lines used in this study had normal euploid karyotypes and validated 
expression levels of pluripotency markers as assessed by immunocytochemistry, qPCR, and/or 
by the PluriTest, a bioinformatics assay developed by Muller and colleagues to quantify 
pluripotency ( Muller et al., 2008). Multiple clonal lines for each subject were used in our 
experiments to decrease the influence of line-specific variability. See Supplemental materials for 
more details. 
Differentiation of early forebrain neuroprogenitors 
Dual-SMAD inhibition-based forebrain neuroprogenitor differentiation of hiPSC lines was 
performed using our previously published protocols and based on the work of Studer and 
colleagues (Chambers et al., 2009 and Neely et al., 2012). These forebrain neuroprogenitors are 
positive for expression of PAX6, FOXG1,OTX2, and SOX1 ( Neely et al., 2012). 
See Supplemental materials for more details. 
Cell viability/cytotoxicity assay 
Neuroprogenitors were exposed to the metal toxicants on day 6 of neural induction for a period 
of 24 or 48 h as indicated. For fibroblast experiments, cells were plated at a density of 
5 × 104/mL and exposed to toxicants the day after plating. Toxicants included heavy metal 
cations of Cd (Cd2 + as CdCl2), Cu (Cu2 + as CuSO4), Mn (Mn2 + as MnCl2), and MeHg 
(CH3Hg+ as CH3HgCl2). Cell viability was assessed by 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay as previously described with 2 h incubation in 
neuralization medium containing MTT (Williams et al., 2010). 
Alternatively, CellTiter-Blue assay (Promega) was used to measure cell viability. At 2 h prior to 
the completion of the 24-hour exposure period, 20 μL of CellTiter-Blue reagent (Promega) was 
added to each well. Prior to this addition, cell lysis buffer was added to several wells to provide 
an accurate fluorescence background for 0% viable cells. The plates were then incubated for 2 h 
at 37 °C. Fluorescence was measured using excitation of 570 nm and emission of 600 nm on a 
POLARstar Omega microplate reader (BMG Labtech). Data were fitted to a normalized inhibitor 
curve with variable slope using Prism5 (GraphPad). 
We also measured the percentage of non-apoptotic cells via forward and side scatter 
measurements by flow cytometry. Single cell events were also identified and gated by forward 
and side scatter. For each experiment, the percentage of non-apoptotic cells was calculated by 
excluding apoptotic cells based on their reduced forward scatter due to cell shrinkage (Healy et 
al., 1998). Gating was set based on the non-apoptotic cells of the vehicle-treated sample for each 
genotype and applied to the Cu-exposed cells of that genotype for each experiment (Figure S4). 
The percentage of non-apoptotic cells is expressed as the percentage of total gated events (Figure 
S4) in each sample that satisfy the single cell gating parameters. 
Semi-quantitative mitochondrial fragmentation analysis 
Semi-quantitative mitochondrial fragmentation analysis was done similar to our previously 
published method, based on previously published methods (Lutz et al., 2009). In brief, on day 6 
of neuralization, neuroprogenitors were passaged as described in the Supplemental materials and 
plated onto 8-well glass slides (Lab-Tek) at a cell density of 1 × 105 cells/mL. Two 
mitochondrial staining methods were used in this work: Mitotracker red dye and 
CellLight Mitochondria-GFP. In the former method, neuroprogenitors were exposed on day 7 of 
neuralization to either vehicle or Cu for 24 h. Following metal exposure, neuroprogenitors were 
incubated with 100 nM Mitotracker red dye (Invitrogen) in neuralization medium for 45 min at 
37 °C. The dye-containing medium was subsequently taken off and cells were incubated in dye-
free neuralization medium for 10 min, washed once with PBS, and fixed with 
4% paraformaldehyde for 10–15 min at room temperature. Alternatively, the mitochondrial-
specific viral transduction system (CellLight Mitochondria-GFP, BacMam 2.0; Invitrogen) was 
used to label mitochondria following the manufacturer's recommended protocol. Briefly, the 
reagent was added to neuroprogenitors on day 6 of neuralization at time of replating at a 
multiplicity of infection (MOI) of 15. Neuroprogenitors were exposed 24 h later to either vehicle 
or Cu for another 24 h then fixed as specified above. Following fixation, immunofluorescence 
staining was performed with PAX6 antibody (Covance, 1:200 dilution). Then cells were 
incubated for 10 min with 2 μM TO-PRO-3 for nuclear counterstaining. Mitochondrial 
fragmentation was analyzed with a confocal microscope (LSM 151 Meta confocal laser scanning 
microscopy system; Carl Zeiss) using 63 × 1.4 NA objective. Mitochondrial fragmentation in 
each of forty randomly chosen PAX6-expressing cells (PAX6 +) for each exposure paradigm 
was assessed at the confocal microscope by a trained observer blinded to cell lineage and 
exposure based on published methods ( Lutz et al., 2009). The number and size of mitochondrial 
fragments, as well as the interconnectivity of the mitochondrial network, were considered in sum 
by the human observer to classify mitochondria of each neuroprogenitor into the semi-
quantitative scale. Using this method, cells were assigned to one of three categories of 
mitochondrial fragmentation: mild, moderate, or severe (an example of each category is 
shown, Fig. 4). Apoptotic and mitotic cells were identified by morphology (shrunken cells with 
condensed nuclei and cells with nuclear fission, respectively) and excluded from analysis. 
Repeated measures general linear model two-way ANOVA (fixed factors of Cu exposure and 
disease group) was performed using SPSS (IBM), with the fragmentation severity categories as 
the repeated measure for each independent sample. Post-hoc analysis was performed by two-
tail t-test or Bonferroni binary comparison (when the number of comparisons exceeded two) to 
identify significant differences between groups in each fragmentation severity class. 
Quantitative mitochondrial morphology analysis 
Mitochondrial morphology was also assessed in a quantitative manner using Mito-Morphology 
macro as previously described (Dagda et al., 2009). The GFP channel of PAX6 + cells of 10 
confocal images from two independent experiments (acquired as above) were converted to RGB 
images in ImageJ (National Institutes of Mental Health). Images were then thresholded to a 
binary image mask using the “Process RGB Image” function of the macro then analyzed using 
the “Measure” function of the macro. Circularity, particle count, and total area of the 
mitochondria were quantified to assess mitochondrial morphological changes as previously 
described (Dagda et al., 2009 and Xie and Chung, 2012). 
Mitochondrial membrane potential analysis 
Neuroprogenitors were exposed on day 7 of neuralization for 24 h and then dissociated using 
Accutase, centrifuged, and resuspended in neuralization medium containing 5 nM of DiIC1(5) 
dye for 15 min. Cells were washed once in PBS and then analyzed using flow cytometry 
(638/658 nm excitation/emission). The samples were analyzed on a Custom Becton Dickson 
five-laser Fortessa analytical cytometer using BD FACSDiva acquisition (BD Biosciences) and 
FlowJo analysis software (Tree Star, Inc.). A total of 10,000 events were acquired, and analysis 
was restricted to non-apoptotic single cell events as determined by light scatter properties (side 
and forward scatters). Apoptotic cells were identified by their relative higher side scatter and 
lower forward scatter due to cell shrinkage and were excluded from the analysis. Experiments 
were done in pairs (CA line versus an SM line, as indicated), and the average fluorescence 
intensity of all viable cells in the Cu-treated cells was normalized to the average intensity for the 
viable vehicle-treated cells for each line. 
Reactive oxygen species (ROS) analysis 
ROS analysis was done as previously described (Aboud et al., 2012). In brief, neuroprogenitors 
were passaged on day 6 of neuralization as described in the Supplemental methods. On day 7, the 
cells were loaded with 2 μM CM-2′,7′-dichlorodihydrofluorescein diacetate (CM-H2DCFDA) 
dye for 30 min in exposure buffer [25 mM HEPES buffer (pH 7.2), 140 mM NaCl, 5.4 mM KCl, 
and 5 mM d-glucose] in the dark at room temperature. The cells were washed with exposure 
buffer to remove excess dye and then exposed to either vehicle (exposure buffer), Cu, or H2O2 in 
exposure buffer. Fluorescence intensity was measured at 37 °C every 5 min using a Beckman 
Coulter DTX 880 microplate reader with excitation at 485 nm (filter bandwidth ± 20 nm) and 
emission at 535 nm (filter bandwidth ± 25 nm). Hydrogen peroxide exposure was used as a 
positive control in each experiment, and a significant concentration-dependent increase by 
hydrogen peroxide in fluorescence was seen across the experimental set (repeated measures 
ANOVA, p < 0.0001, data not shown). 
Additional reagent and method information is available in the Supplemental materials. 
Results 
Sequencing of PARK2 cDNA in the patient derived cells 
Prior clinical genetic testing of patients SM and PM had revealed the inheritance of maternal and 
paternalPARK2 deletion alleles with one allele missing a segment of exon 3 and the other allele 
missing exons 5 and 6. Amplification of cDNA made from fibroblast mRNA with primers 
flanking the deleted exons from both alleles revealed mutant transcripts consistent with the 
genomic deletions identified by clinical genetic testing (Figure S2). Gene sequencing of the 
mutant alleles revealed the presence of both PARK2 deletion mutations in cDNA from the 
patient's (SM) primary dermal fibroblasts (40 bp deletion in exon 3; and 200 bp deletion of exons 
5 and 6; Figure S2). This sequence analysis confirmed the loss of the exons in the genomic DNA 
of SM, originally identified by clinical genetic testing. Additionally, the analysis showed that 
mRNA splicing occurred between the exons adjacent to the deletions in each allele. Both allelic 
deletions result in a frameshift predicted to cause premature termination of translation. These 
frameshift mutations are N-terminal to the conserved RING domain, and, thus, would be 
anticipated to completely abolish ubiquitination function of any potentially translated protein 
( Deshaies and Joazeiro, 2009). Therefore, SM and PM cells are predicted to be functional null 
alleles for PARK2. 
Differential heavy metal sensitivity of SM and CA neuroprogenitors 
We sought to test the hypothesis that PARK2 mutant neuroprogenitors (e.g. patient SM) would 
show elevated sensitivity to PD-relevant environmental risk factors. We tested the viability of 
control (e.g. subject CA) versus patient SM derived neuroprogenitors by MTT assay after 
48 hour exposure to Mn, Cu, Cd, and MeHg, all of which have been implicated in PD-relevant 
neurodegenerative processes and/or as PD environmental risk factors ( Buzanska et al., 
2009, Gorell et al., 1999, Götz et al., 2002, Jomova et al., 2010, Landrigan et al., 2005, Rivera-
Mancía et al., 2010, Squitti et al., 2009, Weiss et al., 2002, Willis et al., 2010 and Xu et al., 
2011). To control for cell line dependent variability, we used multiple clonal hiPSC lines (lines 
CA4 and CA6 for subject CA; lines SM3, SM4, and SM5 for subject SM). Repeated measures 
ANOVA across the concentration response curves demonstrated a heightened sensitivity to Cu 
and Cd but not to Mn or MeHg in SM neuroprogenitors (lines SM3, SM4 and SM5) when 
compared to CA neuroprogenitors (lines CA4 and CA6) ( Fig. 1A). To determine whether the 
differential Cu and Cd sensitivity was also observed in non-neural cell types between the same 
human subjects we generated 48 hour Cu and Cd cytotoxicity concentration–response curves by 
MTT assay in the primary epidermal fibroblasts used to generate the hiPSC lines. No significant 
sensitivity differences to Cu or Cd ( Fig. 1B) viability by MTT assay were observed, suggesting 
at least some cell type dependence of the differential metal sensitivity between these subjects. 
 
Fig. 1. SM neuroprogenitors but not fibroblasts show increased sensitivity to Cd and Cu toxicity. 
(A) Neuroprogenitor survival curves measured by MTT assay after 48 hr exposure to Mn, MeHg, 
Cu, and Cd (CA: CA4, CA6 at N = 6 or 8; SM: SM3, SM4, SM5 at N = 7 or 8). Error bars 
represent ± SEM. (B) The primary dermal fibroblast lines were exposed to Cd or Cu, and cell 
viability was measured by MTT assay (Cu: CA, n = 7; SM, n = 7; Cd: CA, n = 3; SM, n = 3). 
Statistical analysis for genotype effects was performed by two-way repeated measures ANOVA. 
Pairwise post-hoc analysis with Bonferroni correction is indicated between CA and SM hiPSC 
lines as *p < 0.05, ***p < 0.001. Error bars represent ± SEM. 
We decided to further examine the genotype-dependent/subject-dependent differences in Cu 
cytotoxicity, rather than Cd, given the broader concentration response curve and the redox 
potential of Cu that allows it to participate in Fenton chemistry. We saw similar genotype-
dependent differences in viability following 24-hour Cu exposure between CA control cells and 
the PARK2 mutant neuroprogenitors from both SM and PM (Figure S3) by the CellTiter-Blue 
assay, which quantifies viable cells by measuring total cytoplasmic, microsomal, and 
mitochondrial reductase activity ( Gonzalez and Tarloff, 2001). Since both MTT and CellTiter-
Blue viability assays depend, at least in part, on mitochondrial reductase activity, we sought to 
confirm if the effects observed by these assays included decreased cell viability, rather than just 
changes in total mitochondrial reductase activity. Preliminary studies ruled out the use of the 
lactate dehydrogenase (LDH) assay for this purpose because the presence of Cu in the media (as 
low as 25 μM) significantly impaired detection of LDH as previously shown in the literature 
( Pamp et al., 2005). Therefore, we utilized measurement of non-apoptotic cells by flow 
cytometry as a non-mitochondrial dependent assessment of cytotoxicity following 24-hour 
vehicle or 50 μM Cu exposure in control CA and PARK2 mutant SM neuroprogenitors 
( Fig. 2 and Figure S4). This was performed by measuring the percentage of non-apoptotic cells 
(apoptotic cells have reduced forward scatter) from all single cell events. Two-way ANOVA 
revealed significant differences in viability due to Cu exposure (F1,16 = 41.76, p < 0.001), 
genotype (F1,16 = 14.33, p = 0.002), and a Cu × genotype interaction effect (F1,16 = 15.39, 
p = 0.001). Post-hoc analysis demonstrated a significant decrease in percentage of non-apoptotic 
Cu-exposed SM neuroprogenitors versus both vehicle (p < 0.001) and Cu-exposed CA 
neuroprogenitors (p < 0.001); as well as a significant decrease in viability of Cu-exposed CA 
neuroprogenitors compared to the vehicle-exposed CA group (Fig. 2). No difference in baseline 
percentage of non-apoptotic cells was observed between CA and SM. Overall we found a 
consistent increase in sensitivity of SM neuroprogenitors to Cu cytotoxicity that includes 
increased apoptosis and loss of cellular reductase activity. 
 
Fig. 2. SM neuroprogenitors show a stronger reduction in the non-apoptotic cell population 
following Cu exposure. Gating for non-apoptotic cells was performed based on the forward and 
side scatter properties of the vehicle-exposed control group in each independent experiment as 
shown in Figure S4. Percentage of non-apoptotic cells is plotted. Apoptotic cells have decreased 
forward scatter properties due to cell shrinkage. Data collected across 5 independent paired 
experiments (CA6:SM4 n = 2, CA6:SM5 n = 2, CA11:SM14 n = 1, total n = 5). Statistical 
analysis was performed by two-way ANOVA and paired two-tailedt-test for post-hoc analysis 
(*** or ^^^ indicates p < 0.001, absence of a symbol indicates no significant difference p > 0.05). 
* indicates a significant difference within genotype between exposures, and ^ indicates a 
significant difference between genotypes with the same exposure. Error bars represent + SEM. 
One possible hypothesis to explain the increased sensitivity to Cu cytotoxicity is elevated 
cellular uptake of Cu in the SM neuroprogenitors. Therefore, we measured the levels of 
intracellular Cu following a 24-hour exposure to 50 μM Cu by graphite furnace atomic 
absorption spectroscopy (GFAAS). No differences in intracellular Cu levels in vehicle or Cu 
treated SM (SM5) and CA (CA6) neuroprogenitors were observed (Fig. 3). 
 
Fig. 3. Total Cu accumulation is not different between SM and CA neuroprogenitors. CA (CA6) 
and SM (SM5) neuroprogenitors were treated with either vehicle (Veh) or 50 μM Cu (Cu) for 
24 h, and total cellular Cu levels were assessed by GFAAS (Vehicle n = 3; Cu n = 5). Two-way 
ANOVA was used for statistical analysis. Error bars represent + SEM. 
Elevated mitochondrial fragmentation due to Cu exposure in SM and PM neuroprogenitors 
We hypothesized that the increased sensitivity of SM and PM neuroprogenitors to Cu was due to 
an enhanced susceptibility of the mitochondria to oxidative damage. To evaluate this, we 
performed a large study with hiPSC lines from each of three control subjects (CA11, CE6 and 
CF1) and two lines each from SM and PM (SM3, SM14, PM12, and PM17). We assessed 
mitochondrial fragmentation by semi-quantitative assessment of severity using a blinded 
observer in two independent experiments each with 3 control lines (total n = 6 across 2 
experimental days) and 4 PARK2 mutant lines (total n = 8 across 2 experimental days) in 24-hour 
vehicle or 100 μM Cu-exposed PAX6 + neuroprogenitors ( Fig. 4). Cellular mitochondrial 
fragmentation of individual PAX6 + neuroprogenitors was classified into a 3-level semi-
quantitative scale including minimal, moderate, and severe by a trained observer (see 
examples, Fig. 4A). PAX6 + cells were selected prior to visualizing the mitochondria, and then, 
stained mitochondria of the selected neuroprogenitor were visualized by scanning through the z-
axis to inform the scoring decision. Two-way repeated measures (RM)-ANOVA revealed 
significant differences in severity of fragmentation due to Cu exposure (F2,23 = 86.753, 
p < 0.001), genotype (F2,23 = 7.604, p = 0.003), and a Cu × genotype interaction effect 
(F2,23 = 6.448, p = 0.006) ( Fig. 4B). Repeated measures ANOVA of vehicle treated 
neuroprogenitors found no differences between SM/PM versus control (CA11, CE6, CF1) 
(F2,11 = 0.314, p = 0.737), while neuroprogenitors exposed to Cu had a significant difference in 
the severity of fragmentation (F2,11 = 9.630, p = 0.004) between SM/PM versus control. Post-hoc 
examination of the data demonstrated that both SM (p < 0.05) and PM (p < 0.05) 
neuroprogenitors showed significantly more mitochondrial fragmentation than control 
neuroprogenitors following Cu exposure (fewer cells with minimal fragmentation, and more cells 
with severe fragmentation). No significant differences in fragmentation were observed under 
vehicle exposure conditions between control and PD lines. 
 
Fig. 4. Enhanced Cu-dependent mitochondrial fragmentation in SM/PM neuroprogenitors. Forty 
individual PAX6 + neuroprogenitors were scored into three severity classes of mitochondrial 
fragmentation (minimal, moderate and severe) for each independent sample, and the percentage 
of cells in each severity category was determined. (A) Representative images of mild, moderate, 
and severe categories of mitochondrial fragmentation for the semi-quantitative analysis. (B) 
Quantification of mitochondrial fragmentation in control (CA11, CE6, CF1), SM (SM3, SM14) 
and PM (PM12 and PM17) neuroprogenitors after a 24 hr exposure to vehicle or 100 μM Cu. 
Two independent experiments were performed with each line for a total of n = 6 control 
experiments; n = 8 SM/PM experiments (n = 4 SM; n = 4 PM). Analysis was performed using 
repeated measures ANOVA (across the three severity categories) and post-hoc t-test (columns 
are labeled with ‘a’ or ‘b’ to designate significant differences, p < 0.05). Error bars 
represent ± SEM. 
We then applied a quantitative analysis of mitochondrial morphology on a subset of 
mitochondrial images using Mito-Morphology macro, an ImageJ based program, as previously 
described (Dagda et al., 2009). 10 images were randomly selected from two independent 
experiments (5 images from each) for each exposure condition and processed into a binary image 
mask for analysis by the macro (four representative processed images for each experimental 
group are provided in Fig. 5A). Automated analysis of the mitochondrial morphology was 
performed for circularity, segment/particle number, and total area. Two-way ANOVA revealed a 
significant difference in circularity due to Cu exposure (F1,36 = 14.46, p < 0.001), genotype 
(F1,36 = 13.35, p < 0.001), and a Cu × genotype interaction effect (F1,36 = 5.946, p = 0.02). Post-
hoc analysis demonstrated a significant increase in circularity in Cu-exposed SM 
neuroprogenitors compared to both vehicle-exposed SM neuroprogenitors (p < 0.001) and Cu-
exposed CA neuroprogenitors (p = 0.02) (Fig. 5B). Two-way ANOVA also revealed a significant 
difference in the number of mitochondrial segments due to Cu exposure (F1,36 = 17.21, 
p < 0.001) and a Cu × genotype interaction effect (F1,36 = 6.31, p = 0.02). However, genotype did 
not have a significant effect. Post-hoc analysis demonstrated a significant increase in the number 
of mitochondrial segments in Cu-exposed SM neuroprogenitors compared to both vehicle-
exposed SM neuroprogenitors (p < 0.001) and Cu-exposed CA neuroprogenitors (p = 0.006) 
(Fig. 5C). No significant differences were found in circularity or mitochondrial count between 
vehicle-exposed and Cu-exposed CA neuroprogenitors. No significant change in total 
mitochondrial area was observed between these groups either (Fig. 5D). Taken together, the 
automated Mito-Morphology analysis corroborated our findings by semi-quantitative analysis of 
increased severity of mitochondrial fragmentation by Cu exposure in SM neuroprogenitors 
relative to control neuroprogenitors. 
 
 
Fig. 5. Quantitative mitochondrial analysis of Cu-exposed neuroprogenitors. Quantitative 
analysis of mitochondrial morphology was performed using the ImageJ Mito-Morphology 
macro. Randomly selected PAX6 + neuroprogenitors were imaged by an observer blinded to 
genotype or exposure condition from two independent experiments (5 images from each, total 
n = 10) for both vehicle and Cu exposed CA6 and SM3 neuroprogenitors. (A) Four 
representative, binary image masks from each treatment category are shown for visual 
comparison. Quantitative measures were assessed by the macro including (B) mitochondrial 
circularity, (C) total number of mitochondrial segments/particles, and (D) total mitochondrial 
surface area of the binary image masks. Statistical analysis was performed by two-way ANOVA 
and two-tailed t-test for post-hoc analysis (*** or ^^^ indicates p < 0.001; ^^ indicates p < 0.01). * 
symbol indicates significant difference as compared to the vehicle-treated group of the same 
genotype, and ^ symbol represents significant difference compared to Cu-exposed group of the 
other genotype. Error bars represent + SEM. 
Lower threshold for Cu-dependent mitochondrial fragmentation in SM neuroprogenitors 
We hypothesized that the mitochondria of the PD risk group neuroprogenitors are sensitive to 
lower concentrations of Cu than the control group neuroprogenitors. To evaluate this hypothesis, 
we assessed mitochondrial fragmentation in PAX6 + neuroprogenitors derived from 3 SM lines 
(SM3, SM4 and SM5) and 2 control lines (CA6 and CB5) with concentrations of Cu at 10 μM, 
25 μM, and 50 μM (Fig. 6 and S5). We performed 8 independent paired experiments, each one 
with a single SM line and control line. Two-way repeated measures ANOVA of the complete 
data set revealed significant differences in severity of fragmentation due to Cu-exposure 
(F6,112 = 17.912, p < 0.001), genotype (F2,55 = 110.259, p < 0.001) and a Cu × genotype 
interaction effect (F6,112 = 6.973, p < 0.001) similar to what was seen at 100 μM Cu in the 
experiment above (Fig. 4). Analysis of the 10 μM Cu exposure data revealed significantly 
increased fragmentation severity in the SM neuroprogenitors but not the controls (Fig. 6). Both 
25 and 50 μM Cu caused increased fragmentation in both groups with greater fragmentation 
severity in SM (Figure S5). Therefore, the lowest observable exposure level (LOEL) to cause 
alteration in mitochondrial structure is at most 10 μM for SM and ~ 25 μM for controls. In 
addition, a subtle but significant difference (p = 0.017) in baseline (vehicle exposure) 
fragmentation was observed between SM and control neuroprogenitors. 
 
Fig. 6. Decreased Cu-dependent LOEL for mitochondrial fragmentation in SM neuroprogenitors. 
Eight independent experiments were performed with pairs of control versus SM 
neuroprogenitors (CA6:SM3 n = 2, CA6: SM4 n = 2, CA6:SM5 n = 2, CB5:SM5 n = 2, total 
n = 8) exposed to vehicle or 10 μM Cu. Mitochondrial fragmentation was scored by a blind 
observer into three severity categories (minimal, moderate, or severe) for 40 PAX6 + 
neuroprogenitors for each sample. For concentration comparisons * for p < 0.05, ** p < 0.01, 
*** p < 0.001 by t-test. Error bars represent + SEM. 
Cu toxicity is associated with perturbed mitochondrial membrane potential 
As an independent assessment of mitochondrial function, we assessed the mitochondrial 
membrane potential in CA (lines CA6 and CA11) and SM (lines SM4, SM5, and SM14) 
neuroprogenitors using flow cytometry. Only live single cells were included in the analysis 
(Figure S4). We observed that Cu exposure resulted in a decreased mitochondrial membrane 
potential in the majority of SM neuroprogenitors but only in a minority of CA control 
neuroprogenitors (see representative experiment, Fig. 7 upper panels). Similar effects were 
observed in 5 of 5 independent experiments. To quantify this difference in mitochondrial 
membrane potential, we compared the DiIC1(5) signal intensities and observed significantly 
decreased membrane potential in Cu-exposed SM neuroprogenitors compared to control 
neuroprogenitors (Fig. 7 lower panel) (paired t-test p = 0.011). 
 
Fig. 7. Decreased mitochondrial membrane potential by Cu-exposure is more severe in SM 
neuroprogenitors than control. (Upper two panels) Representative flow cytometry experiment 
using DiIC1(5) fluorescence as an indicator of mitochondrial membrane potential after a 24 hr 
exposure to 50 μM Cu in CA6 and SM5. (Lower graph) Mean normalized fluorescence intensity 
of Cu-exposed neuroprogenitors. Data represent single live cell events assessed by flow 
cytometry across 5 independent paired experiments (CA6:SM4 n = 2, CA6:SM5 n = 2, 
CA11:SM14 n = 1, total n = 5). Statistical analysis was performed by a paired two-tailed t-test 
(p = 0.011). Error bars represent + SEM. 
Increased ROS production in SM neuroprogenitors prior to mitochondrial fragmentation 
We hypothesized that the increased mitochondrial fragmentation of SM neuroprogenitors may be 
caused by increased Cu-dependent generation of reactive oxygen species (ROS). Exposure to Cu 
at 50, 100, and 200 μM for 30 min resulted in significantly higher levels of ROS in SM (lines 
SM3 and SM14) compared to CA neuroprogenitors (lines CA6 and CA11) whereas baseline 
ROS levels were not significantly different between cells from the two subjects (Fig. 8). Because 
these measurements were taken after only 30 min of Cu exposure, the elevated ROS must occur 
prior to Cu-induced mitochondrial fragmentation seen at 24 h. This suggests that elevated Cu-
induced oxidative stress is a potential mechanism by which SM has increased Cu-dependent 
mitochondrial fragmentation. The baseline mitochondrial structure differences between SM/PM 
and control may be the cause for this differential ROS generation. 
 
Fig. 8. SM neuroprogenitors have greater ROS production in the presence of Cu. ROS 
generation in neuroprogenitors was measured using a DCF-dye based assay after a 30 minute 
exposure to Cu. Paired CA/SM experiments were performed (CA6:SM3 n = 2, CA6:SM14 n = 3, 
CA11:SM3 n = 2, total n = 7). Statistical analysis for genotype effects was by two-way repeated 
measures ANOVA. Pairwise post-hoc analysis with Bonferroni correction is indicated between 
CA and SM hiPSC lines as * p < 0.05, *** p < 0.001. Error bars represent + SEM. 
Discussion 
Cu has been implicated in the etiology of PD, and its concentration is altered in the blood and 
substantia nigra of PD patients (Boll et al., 2008, Dexter et al., 1991 and Gorell et al., 1999). Our 
data show that increased sensitivity to Cu exposure in neuroprogenitors with high genetic risk for 
PD is associated with elevated ROS generation and a failure to maintain mitochondrial integrity, 
known toxicological mechanisms of Cu toxicity (Gyulkhandanyan et al., 2003). Our data are 
consistent with recent reports examining hiPSCs from PD patients or isogenic lines with 
mutations in PD-related genes that report mitochondrial deficits and increased sensitivity to other 
disease-relevant oxidative stressors (e.g. 6-hydroxydopamine, paraquat, maneb, and rotenone) in 
hiPSC derived neural cells (Byers et al., 2011, Cooper et al., 2012, Imaizumi et al., 
2012, Nguyen et al., 2011, Ryan et al., 2013, Sánchez-Danés et al., 2012 and Seibler et al., 
2011). The heightened vulnerability to Cu we report strongly implicates exposure to this metal 
(and perhaps Cd as well) as a potential compounding risk factor for patients with a family history 
of PD. These data, along with recent papers showing alterations in zinc homeostasis coupled 
with mitochondrial dysfunction in patient derived neuroprogenitors 
with ATP13A2/PARK9 mutations ( Kong et al., 2014, Park et al., 2014 and Tsunemi and Krainc, 
2014), strongly implicate alterations in metal biology as a major environmental modifier of 
genetic risk alleles for PD. 
Our data support a hypothesis in which failure to maintain mitochondrial function and integrity 
during heavy metal exposure may contribute to gene–environment interactions underlying PD 
associated with mutations in PARK2. These findings are consistent with previous research 
demonstrating that loss of PARK2 function causes mitochondrial dysfunction and sensitivity to 
oxidative stress ( Grünewald et al., 2010,Gyulkhandanyan et al., 2003, Mortiboys et al., 
2008, Pacelli et al., 2011, Pilsl and Winklhofer, 2012, Saini et al., 2010 and Ved et al., 2005). 
Two studies have investigated the effects of PARK2 mutations in genetic model organisms and 
did not observe genotype-dependent survival differences due to Cu-supplemented food ( Saini et 
al., 2010 and Ved et al., 2005). However, Saini and colleagues did report exacerbation of a 
neuronal Cu toxicity assay in Drosophila melanogaster (rough eye phenotype) 
carrying PARK2 mutations. This difference, relative to our observed increased vulnerability to 
Cu cytotoxicty in the context of PARK2mutant human neuroprogenitors, may very well be 
explained by systemic Cu homeostatic processes including gastrointestinal regulation of Cu 
uptake that would not be accounted for in a cellular model system. Future studies will be needed 
to resolve the complex role that systemic metal homeostatic control plays in alteration of 
environmental risk by PARK2 and other PD-related genetic risk factors. 
We previously reported a decrease in net cellular Mn uptake following Mn exposure in SM 
neuroprogenitors versus control, despite equivalent Mn cytotoxicity (Aboud et al., 2012). This 
lack of difference in Mn cytotoxicity between control and SM neuroprogenitors appears to be 
due to compensatory neuroprotective changes that decrease Mn uptake in the PARK2 mutant 
neuroprogenitors ( Aboud et al., 2012). As no differences in the accumulation of intracellular Cu 
were observed, the heightened sensitivity of PARK2mutant neuroprogenitors to Cu likely reflects 
either decreased capacity to tolerate Cu toxicity (e.g. failure of antioxidant defense mechanisms) 
or alterations in the biological processes that augment mechanisms of Cu cytotoxicity (e.g. 
decreased Cu chaperone capacity leading to increases in free Cu levels). Further study will be 
needed to investigate whether this gene by toxicant interaction is specific to Cu or if it occurs for 
a broad range of oxidative stressors, such as iron or mitochondrial inhibitors, which are also 
implicated as environmental modifiers or risk factors for parkinsonism ( Peng et al., 2010, Saini 
et al., 2010 and Ved et al., 2005). 
Conclusions 
We report that neuroprogenitors from an EOPD patient and a preclinical PD patient both 
carrying biallelic loss-of-function mutations in PARK2 are highly susceptible to mitochondrial 
toxicity by a subset of heavy metal toxicants compared to neuroprogenitors from 4 different 
control human subjects. This is the first report of altered cytotoxic vulnerability of PD patient-
derived neuroprogenitors with PARK2 mutations to widespread environmentally relevant 
neurotoxicants. Specifically, we found that hiPSC-derived neuroprogenitors from a preclinical 
PD subject with PARK2 loss of function alleles (SM) exhibit heightened vulnerability to Cu and 
Cd cytotoxicity but no difference in sensitivity to Mn or MeHg relative to control 
neuroprogenitors. The heightened sensitivity to Cu in this patient was also observed in hiPSCs 
derived neuroprogenitors from his brother (PM), who shares the same PARK2 susceptibility loci 
and other familial risk factors and who was diagnosed with EOPD. We further report that the 
heightened sensitivity of SM neuroprogenitors to Cu resulting in a decreased lowest observable 
effect level (LOEL) for mitochondrial toxicity by Cu exposure ( Fig. 6). Our data support the 
hypothesis that genetic predisposition to PD can decrease the “safe” exposure threshold to 
environmental risk factors. Our data also support the potential utility of hiPSC-based 
neuroprogenitor model systems to define individualized environmental risk. Further research is 
warranted to determine whether individuals with other genetic PD risk factors may have 
increased risk if exposed to Cu, Cd, or other heavy metals in their environment. 
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